BridgeBio Pharma Gross Profit 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly gross profit history and growth rate from 2018 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- BridgeBio Pharma gross profit for the quarter ending June 30, 2026 was $0.229B, a 113.85% increase year-over-year.
- BridgeBio Pharma gross profit for the twelve months ending June 30, 2026 was $0.673B, a 196.87% increase year-over-year.
- BridgeBio Pharma annual gross profit for 2025 was $0.481B, a 120.67% increase from 2024.
- BridgeBio Pharma annual gross profit for 2024 was $0.218B, a 3079.58% increase from 2023.
- BridgeBio Pharma annual gross profit for 2023 was $0.007B, a 90.76% decline from 2022.
|
BridgeBio Pharma Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $481 |
| 2024 | $218 |
| 2023 | $7 |
| 2022 | $74 |
| 2021 | $67 |
| 2020 | $8 |
| 2019 | $38 |
|
BridgeBio Pharma Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2026-06-30 | $229 |
| 2026-03-31 | $185 |
| 2025-12-31 | $146 |
| 2025-09-30 | $114 |
| 2025-06-30 | $107 |
| 2025-03-31 | $114 |
| 2024-12-31 | $4 |
| 2024-09-30 | $2 |
| 2024-06-30 | $2 |
| 2024-03-31 | $211 |
| 2023-12-31 | $1 |
| 2023-09-30 | $3 |
| 2023-06-30 | $1 |
| 2023-03-31 | $1 |
| 2022-12-31 | $1 |
| 2022-09-30 | $0 |
| 2022-06-30 | $73 |
| 2022-03-31 | $0 |
| 2021-12-31 | $11 |
| 2021-09-30 | $1 |
| 2021-06-30 | $54 |
| 2021-03-31 | $0 |
| 2020-12-31 | $0 |
| 2020-09-30 | $8 |
| 2019-12-31 | $14 |
| 2019-09-30 | $24 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |